ProCE Banner Activity

Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape

Podcast Episodes
Listen as experts answer common questions on current therapeutic options for patients with relapsed/refractory multiple myeloma.

Released: October 24, 2022

Expiration: October 23, 2023

Share

Provided by

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Director, Myeloma Clinical and Cellular Therapy Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: Amgen, AbbVie, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol-Myers Squibb, Karyopharm, Oncopeptides, Takeda.